To the Editor Drs Fralick and Kesselheim raised concerns about desmopressin nasal spray (Noctiva, Serenity Pharmaceuticals), its approval by the US Food and Drug Administration (FDA) for nocturia, potential safety issues, and clinical effectiveness. Their Viewpoint contains misstatements involving the clinical data, the program, and the basis for FDA approval.